| IL-33, ST2, and ILC Pathways | Lifetime | 3 | DE 1 | 99.90 |
| Inflammatory Bowel Disease | Lifetime | 7 | DE 2 | 99.95 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 18 | DE 2 | 99.82 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 32 | DE 3 | 99.71 |
| Immune Cell Function and Interaction | Lifetime | 101 | DE 4 | 99.85 |
| Microscopic Colitis | Lifetime | 24 | DE 2 | 99.79 |
| Whipple's Disease and Interleukins | Lifetime | 2 | DE 1 | 99.61 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 98 | DE 10 | 99.42 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 47 | DE 8 | 99.47 |
| COVID-19 Clinical Research Studies | Lifetime | 217 | DE 9 | 98.94 |
| NF-κB Signaling Pathways | Lifetime | 63 | DE 8 | 99.18 |
| Esophageal Cancer Research and Treatment | Lifetime | 121 | DE 4 | 99.18 |
| Eosinophilic Esophagitis | Lifetime | 116 | DE 9 | 99.26 |
| Immune Response and Inflammation | Lifetime | 290 | DE 17 | 99.23 |
| Gastric Cancer Management and Outcomes | Lifetime | 387 | DE 20 | 99.11 |
| T-cell and B-cell Immunology | Lifetime | 382 | DE 22 | 99.23 |
| Colorectal Cancer Screening and Detection | Lifetime | 237 | DE 6 | 98.97 |
| Long-Term Effects of COVID-19 | Lifetime | 267 | DE 7 | 97.69 |
| Mycobacterium research and diagnosis | Lifetime | 316 | DE 8 | 98.29 |
| Gastrointestinal Bleeding Diagnosis and Treatment | Lifetime | 85 | DE 8 | 98.03 |
| Gut microbiota and health | Lifetime | 517 | DE 21 | 98.29 |
| Gastrointestinal disorders and treatments | Lifetime | 442 | DE 27 | 98.20 |
| Cancer Research and Treatments | Lifetime | 444 | DE 17 | 97.61 |
| Cancer Cells and Metastasis | Lifetime | 773 | DE 65 | 97.03 |
| Celiac Disease Research and Management | Lifetime | 211 | DE 7 | 96.78 |
| Systemic Lupus Erythematosus Research | Lifetime | 986 | DE 46 | 97.30 |
| Autoimmune and Inflammatory Disorders | Lifetime | 297 | DE 20 | 95.84 |
| Liver Diseases and Immunity | Lifetime | 534 | DE 42 | 96.02 |
| Diverticular Disease and Complications | Lifetime | 626 | DE 22 | 95.34 |
| Digestive system and related health | Lifetime | 687 | DE 33 | 94.53 |
| Inflammasome and immune disorders | Lifetime | 988 | DE 73 | 92.69 |
| TGF-β signaling in diseases | Lifetime | 688 | DE 31 | 91.76 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 4 | DE 1 | 99.54 |
| Inflammatory Bowel Disease | 2021-2025 | 21 | DE 2 | 99.71 |
| Immune Cell Function and Interaction | 2021-2025 | 79 | DE 4 | 98.66 |
| T-cell and B-cell Immunology | 2021-2025 | 104 | DE 8 | 96.30 |
| Whipple's Disease and Interleukins | 2021-2025 | 1 | DE 1 | 93.82 |
| Microscopic Colitis | 2021-2025 | 82 | DE 6 | 98.54 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 92 | DE 8 | 96.68 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 405 | DE 18 | 94.44 |
| Mycobacterium research and diagnosis | 2021-2025 | 316 | DE 12 | 91.41 |
| Immune cells in cancer | 2021-2025 | 892 | DE 40 | 88.47 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 551 | DE 44 | 88.31 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 234 | DE 17 | 84.26 |
| Gastrointestinal disorders and treatments | 2021-2025 | 592 | DE 25 | 85.99 |
| Gastrointestinal motility and disorders | 2021-2025 | 465 | DE 10 | 86.10 |
| Eosinophilic Esophagitis | 2021-2025 | 815 | DE 28 | 84.75 |
| Celiac Disease Research and Management | 2021-2025 | 263 | DE 13 | 84.42 |
| Liver Diseases and Immunity | 2021-2025 | 551 | DE 31 | 83.84 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 780 | DE 51 | 84.25 |
| Cell Adhesion Molecules Research | 2021-2025 | 662 | DE 74 | 73.37 |
| Digestive system and related health | 2021-2025 | 753 | DE 19 | 62.71 |
| Phonocardiography and Auscultation Techniques | 2021-2025 | 544 | DE 16 | 62.11 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 972 | DE 30 | 36.35 |
